🏅 FDA Orphan Designation
ATryn
recombinant human antithrombin
Manufacturer: GTC Biotherapeutics, Inc.
FDA-Approved Indications (2)
Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndromeOrphan Designation
Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.
AceruloplasminemiaOrphan Designation
Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients
Population: all ages
Indications & Usage
Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.
💙 Support Programs
View all →ATryn
GTC Biotherapeutics, Inc.
ATryn
GTC Biotherapeutics, Inc.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.